View Older Stories View More Recent Stories

Jul 17, 2017 09:00AM Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
Jun 20, 2017 09:08AM Ligand Pharma (LGND) Partner Melinta Therapeutics Reports FDA Approval of Baxdela for ABSSSI
Jun 20, 2017 09:00AM Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Jun 1, 2017 09:00AM Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
May 31, 2017 05:39PM Ligand Pharma (LGND) to Receive $10M Royalty Fee Following Sale of Certain Product Rights by CorMatrix to Aziyo Biologics
May 31, 2017 05:35PM Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
May 30, 2017 09:10AM Ligand Pharma (LGND) Announces Worldwide OmniAb Platform License Agreement With xCella Biosciences
May 30, 2017 09:00AM Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
May 22, 2017 09:00AM Ligand to Participate in Two Upcoming Investor Conferences
May 9, 2017 04:01PM Ligand Reports First Quarter 2017 Financial Results
Apr 13, 2017 09:00AM Ligand to Report First Quarter 2017 Results on May 9th
Apr 5, 2017 09:03AM Ligand Pharma (LGND) Announces Commercial License and Supply Agreements with Marinus Pharmaceuticals (MRNS) for Captisol-Enabled Ganaxolone
Apr 5, 2017 09:00AM Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Mar 28, 2017 09:00AM Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology
Mar 9, 2017 08:00AM Ligand to Participate in Upcoming Investor Conference
Feb 28, 2017 04:10PM Ligand Provides Highlights from Today’s Analyst Day Event
Feb 28, 2017 04:04PM Ligand Pharma (LGND) Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene
Feb 28, 2017 04:01PM Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene
Feb 27, 2017 09:07AM Ligand Pharma (LGND) Announces Completion of Enrollment in Phase 2 Trial of LGD-6972 in Type 2 Diabetes
Feb 27, 2017 09:00AM Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes
Feb 23, 2017 04:01PM Ligand Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 14, 2017 04:30PM Dr. Christel Iffland Joins Ligand as Vice President, Antibody Technologies, Expands Team Focused on OmniAb Drug Discovery Platform
Feb 13, 2017 04:30PM Reminder: Ligand to Host Analyst Day on February 28th in New York City
Jan 24, 2017 04:30PM Ligand to Host Analyst Day on February 28th in New York City
Jan 23, 2017 04:30PM Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd
Dec 22, 2016 09:15AM Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib
Dec 22, 2016 08:33AM Ligand Pharma (LGND) Enters Worldwide Platform License Agreement with ONO
Dec 22, 2016 08:30AM Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.
Nov 21, 2016 07:30AM Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Nov 3, 2016 04:01PM Ligand Reports Third Quarter 2016 Financial Results
Oct 24, 2016 09:28AM Ligand Pharma (LGND) Announces Submission of Baxdela NDAs to FDA as ABSSSI Treatment
Oct 24, 2016 09:21AM Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
Oct 13, 2016 09:00AM Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
Oct 10, 2016 06:24AM Ligand Pharma (LGND) Partner Lundbeck Granted FDA Approval of Carnexiv
Oct 7, 2016 06:17PM Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Sep 22, 2016 09:02AM Ligand Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs
Sep 22, 2016 09:00AM Ligand Licenses Four Programs to Seelos Therapeutics
Sep 16, 2016 09:00AM Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.
Sep 13, 2016 08:30AM Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
Sep 7, 2016 09:26AM Ligand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data
Sep 7, 2016 09:25AM Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
Sep 2, 2016 09:00AM Ligand to Participate in Two Upcoming Investor Conferences
Aug 15, 2016 09:04AM Ligand Pharma (LGND) Announces Publishing of Results from Phase 1 Trials with LGD-6972 in Type 2 Diabetes Mellitus
Aug 15, 2016 09:00AM Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism
Aug 4, 2016 08:00AM Ligand Reports Second Quarter 2016 Financial Results
Jul 29, 2016 08:32AM Ligand Pharma (LGND) Enters LTP Tech Licensing Agreement
Jul 29, 2016 08:30AM Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
Jul 14, 2016 09:00AM Ligand to Report Second Quarter Results on August 4th
Jul 8, 2016 09:02AM Ligand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD)
Jul 8, 2016 09:00AM Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences
View More Recent Stories View Older Stories